Uncategorized

Hengrui, Kailera’s oral GLP-1 clears late-stage bar in China but US results still pending

Published

on

New data on Hengrui Pharma and Kailera Therapeutics’ investigational oral GLP-1 have validated the late-stage weight loss asset and paved the road for a regulatory submission in China, but analysts pointed to high rates of nausea and vomiting that could challenge the ongoing U.S. study.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version